Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
| العنوان: | Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine |
|---|---|
| المؤلفون: | J Desoutter, J Gay, C Berthon, L Ades, B Gruson, S Geffroy, I Plantier, A Marceau, N Helevaut, J Fernandes, M Bemba, L Stalnikiewicz, C Frimat, J Labreuche, O Nibourel, C Roumier, M Figeac, P Fenaux, B Quesnel, A Renneville, A Duhamel, C Preudhomme |
| المصدر: | Leukemia. 30:1416-1418 |
| بيانات النشر: | Springer Science and Business Media LLC, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Azacitidine, Gene mutation, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, medicine, Humans, neoplasms, Aged, Aged, 80 and over, Hematology, business.industry, Myelodysplastic syndromes, High-Throughput Nucleotide Sequencing, Myeloid leukemia, Middle Aged, Prognosis, medicine.disease, Survival Rate, Transplantation, Leukemia, Myeloid, Acute, Leukemia, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Mutation, Immunology, Female, Bone marrow, business, 030215 immunology, medicine.drug |
| الوصف: | Elderly patients with acute myeloid leukemia (AML), secondary AML and high-risk cytogenetics AML are generally not candidates as they respond poorly to potentially curative treatment with intensive chemotherapy (ICT) followed or not by allogeneic stem cell transplantation (allo-SCT).1 Azacitidine (AZA) has demonstrated a survival improvement in high-risk myelodysplastic syndromes (MDS) and AML with 20–30% bone marrow (BM) blasts, and is also promising in AML with >30% BM blasts.2, 3, 4 Although gene mutations are now routinely included among the prognostic factors of AML treated with ICT,5 their prognostic impact on AML treated with AZA is unknown. We report prognostic factors, including the mutational status of 18 genes assessed by next-generation sequencing (NGS), in 96 newly diagnosed AML patients who received the first line treatment with AZA. |
| تدمد: | 1476-5551 0887-6924 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0faa3ccf5a19b614e51885b3b7b701fTest https://doi.org/10.1038/leu.2015.314Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....c0faa3ccf5a19b614e51885b3b7b701f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765551 08876924 |
|---|